---
title: "LKPC plans to acquire equity in Hecheng Company to further optimize resource allocation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258035807.md"
description: "LKPC announced plans to acquire 1.9231% equity in Shandong Lukang Hecheng Pharmaceutical Co., Ltd. to optimize resource allocation and improve operational decision-making efficiency. This equity is publicly listed for transfer by the Zoucheng Economic Development Zone Management Committee at the Shandong Property Rights Exchange Center. If the transaction is successful, LKPC will directly hold 100% equity in Hecheng Company, and the scope of consolidated financial statements will remain unchanged"
datetime: "2025-09-19T07:42:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258035807.md)
  - [en](https://longbridge.com/en/news/258035807.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258035807.md)
generator: "portal-rs"
---

# LKPC plans to acquire equity in Hecheng Company to further optimize resource allocation

According to the Zhitong Finance APP, LKPC (600789.SH) announced that Shandong Lukang and Cheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Cheng Company") is a joint venture established by the company and the Management Committee of Zoucheng Economic Development Zone (hereinafter referred to as "Zoucheng Economic Development Zone Management Committee"). The Zoucheng Economic Development Zone Management Committee plans to transfer its 1.9231% equity stake (hereinafter referred to as "Target Equity") in Shandong Lukang and Cheng Pharmaceutical Co., Ltd. through a public listing at the Shandong Property Rights Exchange Center. Based on the overall strategic layout and business development needs, the company intends to bid for the Target Equity through a competitive bidding process to further optimize resource allocation and improve operational decision-making efficiency. After the completion of this transaction, the company will directly hold 100% equity in Cheng Company, and the scope of the company's consolidated financial statements will remain unchanged

### Related Stocks

- [600789.CN](https://longbridge.com/en/quote/600789.CN.md)

## Related News & Research

- [Shenzhen Investment Restructures Connected Deals via Property Transfer and Ends Development Pact](https://longbridge.com/en/news/298067700.md)
- [Mabwell reports Phase Ib/IIa data showing anti-ST2 antibody 9MW1911 cuts COPD exacerbations up to 81%](https://longbridge.com/en/news/298042457.md)
- [Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors](https://longbridge.com/en/news/297890174.md)
- [Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule](https://longbridge.com/en/news/297892535.md)
- [Biocytogen licenses fully human VHH antibody to Qilu Pharma in non-exclusive deal](https://longbridge.com/en/news/297781804.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**